Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment
for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).